DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Drug Use Investigation of COMIRNATY Intramuscular Injection

Completed

Conditions: COVID-19

Interventions: Biological: BNT162b2

First Posted Date: 2021-03-24

Last Posted Date: 2024-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 14570

Registration Number: NCT04815031

Locations: 🇯🇵
PfizerLocal Country Office, Tokyo, Japan

NOAC Portuguese Real World Study

Withdrawn

Conditions: Stroke
Systemic Embolism
Major Bleeding

Interventions: Drug: Apixaban
Drug: dabigatran
Drug: rivaroxaban
Drug: VKAs

First Posted Date: 2021-03-22

Last Posted Date: 2023-04-05

Lead Sponsor: Pfizer

Registration Number: NCT04808934

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Phase 2

Terminated

Conditions: Migraine

Interventions: Drug: BHV-3500 (zavegepant)
Drug: Placebo

First Posted Date: 2021-03-18

Last Posted Date: 2025-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 1753

Registration Number: NCT04804033

Locations: 🇺🇸
Clinical Research Philadelphia, LLC, Philadelphia, Pennsylvania, United States
🇺🇸
Meridian Clinical Research, LLC, Norfolk, Virginia, United States
🇺🇸
Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States

and more 99 locations

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Phase 1

Completed

Conditions: Breast Cancer
Ovarian Cancer
Cachexia
Anorexia
Pancreatic Cancer
Colorectal Cancer
Prostate Cancer
Loss of Appetite
Non-small Cell Lung Cancer
Fatigue

Interventions: Drug: PF-06946860
Drug: Placebo for PF-06946860

First Posted Date: 2021-03-17

Last Posted Date: 2024-01-12

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT04803305

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane Valley, Washington, United States
🇺🇸
MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States

and more 30 locations

Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

Recruiting

Conditions: ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Interventions: Drug: Vyndamax (tafamidis 61mg)

First Posted Date: 2021-03-17

Last Posted Date: 2025-01-31

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT04801329

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Phase 2

Active, not recruiting

Conditions: Lyme Borreliosis

Interventions: Biological: VLA15
Biological: Placebo

First Posted Date: 2021-03-17

Last Posted Date: 2024-11-26

Lead Sponsor: Pfizer

Target Recruit Count: 625

Registration Number: NCT04801420

Locations: 🇺🇸
New England Research Associates, Bridgeport, Connecticut, United States
🇺🇸
Richmond Behavioral Associates, Staten Island, New York, United States
🇺🇸
Chase Medical Research, LLC, Waterbury, Connecticut, United States

and more 16 locations

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: PF-07284892
Biological: cetuximab
Drug: binimetinib
Drug: lorlatinib
Drug: encorafenib

First Posted Date: 2021-03-16

Last Posted Date: 2024-10-22

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT04800822

Locations: 🇺🇸
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States

and more 13 locations

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Phase 1

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Elranatamab (PF-06863135)

First Posted Date: 2021-03-15

Last Posted Date: 2022-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT04798586

Locations: 🇯🇵
Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan
🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan

Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

Phase 4

Completed

Conditions: Hospital-Acquired Pneumonia

Interventions: Drug: Zavicefta, Ceftazidime-Avibactam

First Posted Date: 2021-03-01

Last Posted Date: 2023-08-31

Lead Sponsor: Pfizer

Target Recruit Count: 235

Registration Number: NCT04774094

Locations: 🇨🇳
Qingyuan People's Hospital, Qingyuan, Guangdong, China
🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Hainan General Hospital, Haikou, Hainan, China

and more 50 locations

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Phase 2

Completed

Conditions: Group B Streptococcus Infections

Interventions: Biological: Multivalent Group B streptococcus vaccine
Biological: Tetanus, diphtheria, and acellular pertussis vaccine
Biological: Placebo

First Posted Date: 2021-02-23

Last Posted Date: 2024-05-24

Lead Sponsor: Pfizer

Target Recruit Count: 306

Registration Number: NCT04766086

Locations: 🇺🇸
DM Clinical Research - Brookline, Houston, Texas, United States
🇺🇸
Accellacare - Raleigh, Raleigh, North Carolina, United States
🇺🇸
Accellacare - Wilmington, Wilmington, North Carolina, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy